Park Ridge mayor says city could make ban on nitrous oxide part of ‘broader discussion.' Resident says sales of it ‘may be targeting kids'
As other Chicagoland towns look to ban the sale of nitrous oxide canisters, city of Park Ridge leaders are eyeing a similar halt.
Nitrous oxide — also known as laughing gas — is often used in whipped cream to help create the foam product, and it's used by dentists as a sedative. But municipal leaders are looking at another use for the nimble colorless, odorless gas: It is also used recreationally to get high.
At present, anyone can buy nitrous oxide, and it is sold online and possibly locally. At least one resident said she believes the gas is being marketed to children. However, it's not clear if anyone is selling it in Park Ridge or using it as a recreational drug.
'It's flavored, so obviously they're targeting kids,' Joan Sandrick said during the public comment portion of the May 19 City Council meeting.
Sandrick said she hasn't gone to vape shops locally to see if it's sold in Park Ridge, but based on media coverage of what leaders in south suburban Homer Glen and Manhattan – both located in Will County – she imagines it is.
Manhattan banned nitrous oxide sales in 2024.
The Food and Drug Administration warned consumers in March to avoid inhaling the gas, advising that doing so could be fatal.
'These products are marketed as both unflavored and flavored nitrous oxide canisters and are sold as a food processing propellant for whipped cream and culinary food use,' FDA officials stated in a news release. 'Intentional misuse or inhalation of contents can lead to serious adverse health events, including death.'
At the regular City Council and the Committee of the Whole meetings held May 19, leaders spoke about at least outlawing local sale of the gas to anyone under 21 years old. However, there is no clear date on a ban. Sandrick urged city leaders, who have already addressed regulations on the synthetic THC product Delta 8, to restrict nitrous oxide sales as well.
'We need to see whether this is something we should ban,' said Sandrick. 'We probably should. I would highly encourage you to ban it. It's not safe. It's used in dental practices under strict supervision but it's not flavored and used as an inhalant to get high.'
Mayor Marty Maloney assured Sandrick the council would address the matter. He agreed the city should at least learn about whether or not nitrous oxide is sold and who is buying it and then what to do about it.
'I think the common theme is [that] none of us are very knowledgeable about these types of things and what's being sold in the vape shops,' Maloney said.
The mayor asked if city officials could look into it, and city manager Joe Gilmore said he would.
'I think we can take a broader, macro look at it and see what's available in vape shops,' Gimore told the council. 'We can see what other communities are doing, maybe, and see what else is out there. We can make this a broader discussion, I think.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
16 minutes ago
- Newsweek
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.
Yahoo
an hour ago
- Yahoo
Texas lawmakers pass medical marijuana bill that includes chronic pain
A bill expanding Texas' medical marijuana program is headed to Texas Gov. Greg Abbott's desk. The latest version was negotiated by members of the Texas House and Senate, including several lawmakers representing parts of Tarrant County. A compromise version of House Bill 46 advanced on Sunday, June 1, as negotiated in a conference committee made up of lawmakers from both chambers. It includes a number of recommendations from supporters of medical marijuana on how to improve the program, called the Texas Compassionate Use Program. The bill's measures include: Permitting satellite locations where dispensing organizations can securely store medical marijuana for distribution. Currently the products can only be stored overnight at an organization's main location, creating distribution challenges. Requires the state to have 15 dispensing organizations. At least three are required now, according to the Texas Department of Public Safety. Allows inhaling medical marijuana as an aerosol or vapor. Smoking is still not allowed. It also expands qualifying medical conditions to include: A condition that causes chronic pain. A traumatic brain injury. A terminal illness or condition that requires hospice or palliative care. The version that passed out of the House in May also included glaucoma, degenerative disc disease and spinal neuropathy, and included language specifically folding veterans into the program. The bill defines chronic pain as 'pain that is not relieved with acute, post-surgical, post-procedure or persistent non-chronic pain treatment and is associated with a chronic pathological process that causes continuous or intermittent severe pain for more than 90 days and for which a tetrahydrocannabinol is a viable method of treatment.' The Senate's version had included language that would have required patients to be on an opioid for 90 days before qualifying for the medical marijuana program. That requirement wasn't acceptable to the House, said Rep. Ken King, a Republican from Canadian who authored the bill. 'While we were not able to find agreement on degenerative disc disease, glucoma, spinal neuropathy and veterans, we believe with the new definitions of chronic pain, most of these patients will be covered,' King said. Tony Tinderholt, an Arlington Republican, who was a member of the conference committee, maintained that veterans are covered under the bill. 'The veterans out there watching need to know that the Texas Compassionate Use Program has been protected,' Tinderholt said. The expansion comes as Texas is positioned to ban consumable TCH products, like the delta-8 and delta-a gummies, vapes and drinks that can be found at stores and gas stations across Texas. The ban was a top priority of Lt. Gov. Dan Patrick, who on May 28 held a news conference blasting the THC products. Members of the hemp business community have called for new regulations, like age restrictions, and better enforcement of existing regulations, rather than a ban of the products. The Texas Hemp Business Council has called on Abbott to veto the legislation.
Medscape
2 hours ago
- Medscape
ACURATE Heart Valves Halted After Consequential Study
Boston Scientific has discontinued production of its ACURATE neo2 heart valves following the release of data showing the devices were linked to higher rates of all-cause death, stroke, and rehospitalization than were other commercially available valves. The company reported the decision in a May 28 regulatory filing. 'While data continue to support the performance of the ACURATE valve system when the product's optimized instructions for use are followed, this decision was made based on recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain approvals in global markets and to obtain approval in new markets,' Boston Scientific told Cardiovascular Business . 'Therefore, related commercial, clinical, research and development, and manufacturing activities will cease.' The company said it also would be halting production of its ACURATE PRIME valves, although the reason for that move was not clear. Disappointing Results The decision on the neo2 follows the publication May 21 of two articles from the study, one in the Lancet on the outcomes for patients and the other in the Journal of the American College of Cardiology on a relatively high rate of under-expansion of the valves. Despite its use in 50 other countries, ACURATE neo2 had not yet been approved by the US Food and Drug Administration. The Lancet study, which the company funded, involved 1469 patients undergoing transcatheter aortic valve replacement (TAVR). Its aim was to determine whether ACURATE neo2 was not inferior to its competitors. The randomized, controlled trial found ACURATE neo2 was associated with a 6.6% higher rate of a combined outcome of all-cause death, stroke, and rehospitalization after 1 year than was observed in a control group who received SAPIEN 3 or 3 Ultra or Evolut valves. The rates were also higher for each outcome (hazard ratio: 1.30 for all-cause death, 1.68 for stroke, and 1.57 for rehospitalization). Rates of cardiovascular mortality and myocardial infarction also were significantly higher at the same time point, according to the researchers. ACURATE neo2 was developed after its predecessor, ACURATE neo, a self-expanding valve for TAVR, did not achieve outcomes similar to those of SAPIEN and Evolut valves in randomized controlled trials. A problem with paravalvular leakage was found with ACURATE neo, prompting the development of neo2, which included a sealing skirt to prevent leakage, said Raj Makkar, MD, professor and associate director of the Smidt Heart Institute at Cedars-Sinai Medical Center in Los Angeles, and lead author of both papers. 'The sealing skirt worked, and the valvular regurgitation rates were lower than in ACURATE neo, but they were nonetheless still higher than in the control valves,' said, who receives research support from Boston Scientific as well as other manufacturers of heart valves. In addition to poor results on the longer-term outcomes, the ACURATE neo2 was associated with a lower rate of success, determined by whether the device was installed and operated successfully, did not require further interventions, and was not linked to complications within 30 days. One result was positive for ACURATE neo2. 'The hemodynamics were actually quite good,' Makkar said. 'This trial also highlights that, when it comes to clinical outcomes, it's not just the hemodynamics. A lot of other things come into play.' 'The ACURATE neo2 valve is an easy-to-use valve, and smaller, observational studies had suggested that outcomes were good,' Makkar added. 'But you need the rigor of a randomized controlled trial. In a randomized setting, the clinical outcomes were not as robust as they were with the other valve platforms.' Valve Expansion a Concern In a post-study analysis, the researchers went back to see if they could find any contributing factors to the ACURATE neo2's poorer outcomes. When they reviewed angiograms taken during TAVR procedures, they noticed many of the valves had not fully expanded. 'We found that under-expansion was associated with more frequent primary endpoints in contrast to valves that were properly expanded,' Makkar said. 'If you modified the device such that the radial strength were better, and we did more aggressive pre- and post-dilation, we could perhaps improve the expansion of the valve,' Makkar said. 'But whether that would lead to better clinical outcomes remains to be investigated and proven…. Dilation might increase the risk of some complications, such as stroke and aortic root injury. It is reasonable to try to safely expand the valve, but we should not expand the valve at any cost.' Makkar reported research support from Boston Scientific, Edwards Lifesciences, Medtronic, Abbott, and JenaValve.
